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Abstract
Immunodominant epitopes are few selected epitopes from complex antigens that initiate T cell 
responses. Here, to provide further insights into this process, we use a reductionist cell-free 
antigen processing system composed of defined components. We use the system to characterize 
steps in antigen processing of pathogen-derived proteins or autoantigens and we find distinct paths 
for peptide processing and selection. Autoantigen-derived immunodominant epitopes are resistant 
to digestion by cathepsins, whereas pathogen-derived epitopes are sensitive. Sensitivity to 
cathepsins enforces capture of pathogen-derived epitopes by Major Histocompatibility Complex 
class II (MHC class II) prior to processing, and resistance to HLA-DM-mediated-dissociation 
preserves the longevity of those epitopes. We show that immunodominance is established by 
higher relative abundance of the selected epitopes, which survive cathepsin digestion either by 
binding to MHC class II and resisting DM-mediated-dissociation, or being chemically resistant to 
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cathepsins degradation. Non-dominant epitopes are sensitive to both DM and cathepsins and are 
destroyed.
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Introduction
Immunodominance is a well-established phenomenon whereby a few specific peptides are 
selected as representative epitopes of a given protein antigen to the immune system. A 
restricted response to an antigen might be necessary for keeping the sheer number of 
memory T cells within a narrow range that can be accommodated by lymph nodes, as a 
portion of memory T cells are maintained throughout life.1 Many studies have aimed to 
understand mechanisms of epitope selection and immunodominance; a range of hypotheses 
related to the structural features of antigens2–4, sensitivity to proteases5,6, epitope affinity for 
MHC class II7, T cell precursor frequency8, and T cell receptor affinity for peptide/MHCII9 
have been considered. These studies suggest that the mechanisms evolved for the selection 
of the dominant epitopes is rather complex. Antigen presentation to CD4+ T cells by APCs 
begins by the uptake of exogenous antigens and their processing that involves transfer 
through a series of endosomal compartments containing suitable denaturing environment, 
accessory chaperones, and cathepsins10. Newly synthesized MHCII molecule associates 
with the class II invariant chain (Ii), which targets it to specialized endosomal compartments 
(MIIC) where the Ii is proteolysed until only a fragment known as the class II-associated 
invariant chain peptide (CLIP) remains bound in the MHCII peptide-binding groove. 
Efficient displacement of CLIP from the MHC groove requires the accessory molecule 
HLA-DM in human or H2-M in mice (DM).11 DM functions by inducing conformational 
changes in MHCII/peptide complexes resulting in the release of the bound peptide inducing 
a peptide-receptive MHCII.12 A peptide-receptive MHCII can quickly sample a large pool 
of peptides derived from exogenously acquired proteins and DM helps in shaping epitope 
selection. The molecular detail of the interactions between DM and MHCII hints at a critical 
role for DM in selection of immunodominant epitopes.13 However, this role has not been 
fully evaluated. Importantly, there is no consensus as to when immunodominant epitopes are 
selected. It is not clear at what stage during this process DM exerts its function.
The question is whether epitopes are first cut by the antigen processing enzymes and then 
captured, or epitopes bind to MHCII as full-length proteins or large fragments, and then are 
processed. Different cathepsins and the proper microenvironment to support their functions 
are provided in the MIIC14. Multiple studies using protease inhibitors in combination with 
protease-deficient Tg mice revealed that several enzymes, including cathepsins (Cat) S, L 
and F might contribute to antigen processing and the removal of CLIP15. Asparaginyl 
endopeptidase (AEP), present in the late endosomal compartments, is necessary for cleavage 
and activation of cathepsins16; although a role for generation, as well as destruction of 
antigenic epitopes by AEP have also been reported.17
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To directly address specific questions regarding steps in antigen processing and the selection 
of immunodominant epitopes, we have developed a reductionist antigen processing system 
for MHCII molecules that incorporates defined components and accurately predicts 
immunodominant epitopes from protein antigens.18 The system includes soluble purified 
HLA-DR (DR), CatB, CatH, and CatS that process protein antigens into peptides, and DM. 
Mass spectrometry is used for sequencing the unique peaks derived from each protein. 
Candidate epitopes are verified for accuracy in DR transgenic mice and humans.18 Due to 
the defined molecular composition, this system lends itself to elucidating steps involved in 
antigen processing and the roles individual components play in epitope selection. In this 
study, we addressed determinants of immunodominance. We report that immunodominant 
epitopes from different antigenic sources are selected based on their relative abundance that 
rely on differential sensitivity to cathepsins, or resistance to DM-mediated dissociation.
Results
CA-074ME inhibits processing of type II collagen and H5N1-HA
Cysteine proteases are a major family of intracellular proteases best studied in antigen 
processing by APCs. As mentioned above, CatB, H and S are the only proteases in our cell 
free antigen processing system. To test their roles in dominant epitope selections in cells, we 
used a cell-permeable CatB inhibitor, CA-074ME during the processing and presentation of 
type II collagen and H5N1-HA proteins ex vivo. While CA-074 is a potent inhibitor of CatB, 
addition of methyl ester group to make it cell permeable has made it a partial inhibitor of 
CatS as well. However, upon entry into the cell methyl ester group is lost and the 
remarkable potency of CA-074 as CatB inhibitor is revealed.19 Specific T cells were 
generated in DR1 (DRB1*0101) transgenic mice by immunization with type II collagen 
(CII) derived-epitope CII(280–294), or H5N1-HA derived-epitope, H5N1-HA(259–274), in 
CFA. Cells from draining lymph nodes were cultured in the presence of either peptides, or 
proteins in the presence or absence of the inhibitors. As shown in Fig. 1 and Supplementary 
Fig. 1, addition of CA-074ME in control groups did not affect the presentation of CII and 
H5N1-HA derived epitopes as measured by IFN-γ ELISPOT assay. In contrast, in the 
presence of CA-074ME, processing and presentations of both proteins were completely 
inhibited. These results confirm that cathepsin B is a crucial component of antigen 
processing for the generation of CII(280–294) or HA(259–274) dominant epitopes.
DM alone is not sufficient for selection of CII(280–294)
DM has been proposed as a critical component of the antigen processing machinery 
contributing to the selection of the immunodominant epitopes20. To evaluate this notion, we 
used our reductionist system for the selection of the known DR1 restricted immunodominant 
epitope of bovine CII (bCII)21. Generation of this epitope involves prior digestion by 
gelatinase B (MMP-9). A comparison of mass spectra from five samples incorporating 
MMP-9 pre-cut bCII18 with all, or selected components in the system is shown in Fig. 2. 
Samples a–d contained MMP9 digested bCII peptide mixtures whereas sample 1e served as 
the background lacking bCII (unabridged spectra are shown in Supplementary Fig. 2). The 
known immunodominant bCII peptide appeared as a cluster of variants with different 
posttranslational modifications (PTM) (Fig. 2a–d) and was absent from all background 
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control experiments missing the CII fragments (Fig. 2e and Supplementary Fig. 2e–h). Other 
CII-derived epitopes (shown in blue in Fig. 2a–e) were also detected in samples including 
DR with either DM, or cathepsins (Fig. 2a–c). However, those epitopes disappeared only 
when all the components were present (Fig. 2d). The two most prominent CII-derived 
peptides at m/z 1413 and 1435Da, were sodiated and non-sodiated forms of the same 
peptide, bCII(954–968)2OH (Figure 2a–c). To assess the immunogenicity of these epitope in 
mice, DR1 transgenic mice were immunized with CII protein in CFA and cells from 
draining lymph nodes were cultured in the presence of either peptide. As shown in Fig. 2f, 
cells responded to the dominant epitope as measured by T cell proliferation and IL-2 
production, but did not respond to CII(954–968)2OH peptide, suggesting that CII(954–
968)2OH is not an immunogenic epitope. To confirm the sensitivity of CII(954–968)2OH and 
of the immunodominant epitope to DM, we measured the dissociation kinetics of 
fluorescein-labeled CII(954–968)2OH and CII(280–294) in complex with DR1 in the 
presence or the absence of DM. FL-CII(954–968)2OH peptide showed sensitivity to DM-
mediated dissociation (Fig. 2g). Against our expectations, the CII dominant epitope also 
showed sensitivity to DM-mediated dissociation (Fig. 2h).
The above findings prompted a hypothesis that DM-sensitive non-dominant epitopes are 
dissociated by DM and are digested away by the cathepsins, while the dominant epitopes, 
despite sensitivity to DM, survive the enzymatic digestion and emerge as dominant. To 
verify this hypothesis, we preincubated CII fragments with cathepsins for 3h, 1h, or 15min 
before adding DR1 and DM, or mixed together all the components at once. Fig. 3a–e 
indicates that the clusters of peptides containing the core dominant epitope (m/z 3000–
3500Da range) were present regardless of the length of exposure to the cathepsins. However, 
when all the components were present, cathepsin-sensitive epitopes (shown in blue) were 
digested away (Fig. 3e). To further evaluate these findings, synthetic dominant CII(280–
294) (Fig. 3f) and nondominant CII(954–968)2OH (Fig. 3g) peptides were directly exposed 
to the cathepsins. The dominant epitope was prominently detected at m/z 1471Da after 
exposure to cathepsins (Fig. 3f, middle), whereas the non-dominant peptide was no longer 
detectable (Fig. 3g, middle). A new peptide peak that appeared at m/z 1338 Da was 
sequenced and was not a CII(954–968)2OH derived peptide (Fig. 3g, middle). These 
observations indicate that complexes of DR1/CII immunodominant epitope are sensitive to 
DM-mediated dissociation but resistant to degradation by cathepsins.
Dominant epitopes of HA1 are sensitive to cathepsins
To test if the CII results were applicable to other antigens, we used a well known epitope 
from A/Texas/1/77 influenza strain, HA(306–318).18,22 Contradictory to CII predigestion 
data, nearly all rHA1-derived peptides were degraded by pre-exposure to cathepsins for 3h 
(Fig. 4a). Few rHA1-derived peptides were detectable (shown in blue) after 1h, or 15min 
exposure, but HA(306–318) containing epitope was not found under any condition tested 
(Fig. 4b–c). Peptides containing the immunodominant epitope were identified only when all 
components were mixed together (Fig. 4d, highlighted in red) or when the order of reactions 
were changed to incubation of full-length rHA1 protein with DR1 and DM first, then adding 
the cathepsin mix (Fig. 4e). Other rHA1-derived peptides were also observed at m/z 1955, 
2102, 2265, and 2339Da (highlighted in blue). We surmised that the successful generation 
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of immunodominant peptides from rHA1 protein depends on its capture by DR and editing 
by DM prior to the proteolytic fragmentation of the antigen. These data suggest a different 
temporal relationship between epitope capture and processing for HA versus CII proteins.
To validate cathepsin sensitivity of the dominant epitope of rHA1, synthetic HA(306–318) 
was exposed to the cathepsin mixture. Compared to the sample containing only HA(306–
318) at m/z 1504Da (Fig. 4f, top), cathepsins exposed HA(306–318) became shorter and 
appeared at m/z 1218Da. It was sequenced as PKYVKQNTLK missing LAT at its C-
terminus (Fig. 4f, middle). To test PKYVKQNTLK for binding to DR1, peptide HA(306–
318) was exposed to cathepsins prior to incubation with peptide-receptive DR123 and the 
bound peptides were eluted and assessed by mass spec. While the parallel control peptide 
HA(306–318) was detected, the short peptide HA(306–315) was not found likely due to 
inability to bind DR1. In that sample only the bacculovirus-derived background peptide 
CL(13–23) that co-purifies with DR1 was detected (Supplementary Fig. 3a, middle).
Sensitivity of the HA(306–318) peptide to degradation by the cathepsins was further tested 
by a cellular read out using Clone 1 T cells (CL-1) specific for HA(306–318)/HLA-
DR1.24,25 HA(306–318) peptide was incubated with cathepsin mix, cathepsins were heat-
inactivated, and the sample was used to pulse DR1+ EBV-transformed B cells as APCs. The 
peptide subjected to digestion did not activate CL-1 T cells, whereas the control peptide, 
HA(306–318) without prior cathepsin digestion did (Supplementary Fig. 3b). All the 
experiments above establish that HA(306–318) is sensitive to cathepsin digestion.
We next examined immunodominant epitope from rHA1 of H5N1 strain of influenza, HA 
(259–274)18 and obtained similar results as above. Fig. 5a shows that when H5N1-rHA1 
protein was incubated with DR1 and DM first, followed by cathepsin digestion, unique 
peptide species were detected at m/z 1726, 1813, and 2202Da that shared the same core 
dominant epitope. When H5N1-rHA1 was first digested with cathepsins, a significantly 
lower peak intensity at m/z 1814Da emerged, and the peptides at m/z 1726 and 2202Da 
were no longer present (Fig. 5b) indicating that this epitope might be susceptible to 
cathepsin digestion. Next, sensitivity of H5N1-rHA1 dominant epitope, HA(259–274), to 
cathepsins was examined (Fig. 5d–e). A shorter peptide, SNGNFIAPEY, missing four 
amino acids from the C-terminus of HA(259–274), emerged as a major peak at m/z 1111Da 
(Fig. 5d, middle). Only a trace of the undigested peptide was detected at m/z 1815Da (Fig. 
5d, middle). In a parallel set of experiments, when HA(259–274) was digested with the 
cathepsins prior to incubation with DR1, no trace of the HA(259–274) was detected and 
only the bacculovirus-derived background peptide was found (Fig. 5e). The short peptide 
detected at m/z 1111Da (Fig. 5d, middle) was not captured by DR1 (Fig. 5e, middle). This 
again demonstrates that H5N1-HA derived HA(259–274) epitope is sensitive to degradation 
by the cathepsins in the system, hence protein binding to DR1 should precede peptide 
generation to protect this epitope from fast degradation by the cathepsins. Thus far, we have 
shown that CII dominant epitope is sensitive to DM-mediated dissociation but resistant to 
cathepsin digestion. On the contrary, HA-derived dominant epitopes both showed full 
sensitivity of cathepsins. However, both HA-derived epitopes are insensitive to DM-
mediated dissociation.26 Hence, not all antigens are processed similarly; some bind MHC 
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class II first, and then are processed, while some others are processed into short peptides 
first and then bind to MHC class II.
Protein binds to MHC class II molecules
If processing of antigen takes place after binding of antigen to DR1, a complex of protein 
with MHC class II molecule should be detectable. To test this notion, we used a gentle SDS-
PAGE assay originally used to detect peptide binding to MHC class II in which samples 
were not boiled.27,28 Binding of full-length rHA1 protein to DR1 was detected by its slower 
migrating molecular species in the presence of DR1, rHA1 and DM (Fig. 6a, lane7, and Fig. 
6b lane 4 and 6). Importantly, the Fig. 5b shows that the molecular mass of the DR1/rHA1 
protein complex was estimated ~ 96kD (marked by *) that is the sum of rHA1 (~45kD 
marked by 〉) and DR1 alone (~51kD) (lane 2). In the presence of excess HA(306–318) in 
the reaction, the band intensity at ~96kD was significantly reduced (Fig. 5b, lane 8 and lane 
17) and the new band that appeared matched the migration pattern of HA(306–318)/DR1 
complex (marked by ➢) (Fig. 6b, Lane8, Lane 9). These data indicate that interaction with 
HA1 protein occurred specifically through the peptide-binding groove of DR1. Consistent 
with the role for DM in generating the peptide-receptive conformation of DR molecules, 
inclusion of DM together with DR1 and the rHA1 proteins resulted in more intensely stained 
bands corresponding to the protein/DR1 complexes (Fig. 6a, lane 6 and 7, and in Fig. 6b 
lane 4, 6, 15, and 16).
Simultaneous binding of two DR alleles to H5N1-rHA1
If the full length proteins bind to MHC class II molecules, it should be possible to detect 
simultaneous binding of a stretch of protein to two MHC II alleles that have non-
overlapping epitopes on the same protein BIAcore Surface Plasmon Resonance (SPR) 
instrument. Preformed Biotinylated DR4 in complex with denatured H5N1-rHA1 was 
immobilized on streptavidin coated (SA) BIAcore chip, followed by injection of receptive 
DR1 in the presence of DM (Fig. 6c). The binding of DR1 to the complexes of DR4/H5N1-
rHA1 produced 778 Response Unit RU signal. Injection of compact folded HA(306–318) 
bound DR1 (as negative control) produced 199 RU. This level of binding of DR1/HA(306–
318) sample to HA1 protein is due to the presence of some empty DR1 molecules that were 
not in complex with HA(306–318) and were helped by DM. Binding of peptide receptive 
DR1 to the complexes of DR4/H5N1-rHA1 indicates that more than one MHC class II 
molecules are capable of binding to the H5N1-rHA1 protein. Thus; a) MHC class II 
molecule can bind to protein antigens, b) just like peptide binding, DM enhances binding of 
full-length protein to DR1, and c) binding of protein to DR1 occurs through peptide binding 
groove of DR1 rather than other possible sites.
Autoantigens are less susceptible to cathepsins
So far, we have observed that immunodominant epitopes are either DM-sensitive but 
cathepsin-insensitive, or DM-resistant but cathepsin-sensitive. To expand our sample size, 
we examined few more autoantigens known to induce autoimmune diseases; uveitis-
associated epitopes from retinal antigens, autoimmune thyroiditis-associated epitope from 
thyroglobulin, and myocarditis inducing myosin heavy chain-α. Retinal arrestin [soluble-Ag 
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(S-Ag)] is the antigen that is thought to be involved in uveitis in human and also in murine 
experimental autoimmune uveitis (EAU). Immunodominant epitope of retinal arrestin has 
been identified as hSA(291–306)29, which induces EAU in HLA-DR3 (HLA-DRB1*03:01) 
transgenic mice. Thyroglobulin peptide, Tg(2098–2112), has been identified as an 
immunodominant epitope that induces murine experimental autoimmune thyroiditis (EAT) 
in DR3 bearing transgenic mice.30 Myosin heavy chain-α epitope, Myosin(334–352), has 
been shown to induce myocarditis in A/J mice.31 To test cathepsin sensitivity, synthetic 
hSA(291–306), Tg(2098–2112), and Myosin(334–352) peptides were directly exposed to 
the cathepsin mixture and the reaction products were analyzed. We found that hSA(291–
306) and Tg(2098–2112) lacked susceptibility to cathepsin digestion while being resistant to 
DM-mediated dissociation. Fig. 7a, top panel shows undigested hSA(291–306) at m/z 
1892Da. Upon digestion with cathepsins, the full-length peptide peak at m/z 1892Da was 
minimized and a new peptide peak was detected at m/z 1627Da (Fig. 7a, middle) and 
sequenced as NRERRGIALDGKIK that is missing two amino acids off of the C-terminus. 
Other peptides detected at m/z 1177, 1275, 1346, 1429, and 1487Da were also detected in 
the background sample. Importantly, loss of the two C-terminal residues does not abrogate 
the ability of this peptide to induce EAU in mice.29
We next examined thyroglobulin (2098–2112) peptide for its cathepsin sensitivity which is 
detected at m/z 1669Da (Fig. 7b, top). Cathepsin exposed peptide produced truncated 
versions of the epitope at m/z 1171Da (LSSVVVDPSIR), 1255Da (SVVVDPSIRHF), 
1456Da (LSSVVVDPSIRHF), and 1469Da (SVVVDPSIRHFDV), along with the reduced 
intensity of intact peptide at m/z 1670Da (Fig. 7b, middle).
To test the sensitivity of hSA(291–306) and Tg(2098–2112) to DM-mediated dissociation, 
we measured the dissociation kinetics of fluorescein-hSA(291–306) and fluorescein-
Tg(2098–2112) in complex with DR3 in the presence or the absence of DM. DM 
functionality was tested in a binding assays (Supplementary Fig. 4). When tested for DM 
sensitivity, DM did not facilitate the dissociation of either hSA(291–306), or Tg(2098–2112) 
from DR3 (Fig. 7c–d). These results suggest that these autoantigen derived-epitopes are 
selected as immunodominant by having two advantages; resistance to cathepsin digestions, 
and resistance to DM-mediated dissociation. Sensitivity of Myosin(334–352) to cathepsin 
digestion was examined as with hSA and thyroglobulin peptides. While the majority of 
Myosin(334–352) remained intact after cathepsin digestion, minor fractions of shortened 
epitopes were also detected (Supplementary Fig. 5). Next, we examined Myelin basic 
protein, MBP(84–102) that has been considered as a potential immunodominant epitope in 
relation to multiple sclerosis (MS) restricted to HLA-DR2b (DRB1*15:01)32, and insulin 
B7–23 epitope, a candidate antigen for the induction of diabetes in NOD mice33. When 
MBP(89–101) peptide was directly exposed to the cathepsin mixture, although some 
trimming occurred, the major epitope, VHFFKNIVTPR at m/z 1357Da maintained its 
corresponding anchor residues for binding to DR2b. Interestingly, two shorter peptide 
fragments, FFKNIVTPR at m/z 1121Da, and HFFKNIVTPR at m/z 1258Da, maintained at 
least some of their anchors including the major P4 fitting residues (Supplementary Fig. 
6).34,35 MBP(89–101) peptide has been reported to have two registers for binding to DR2a 
and DR2b. one of the shorter peptides shown above lost P1 anchor for binding to DR2b, and 
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the other lost P9 anchor for binding to DR2a. MBP(89–101) epitope is sensitive to DM-
mediated dissociation36, hence lack of sensitivity to cathepsins allows its 
immunodominance. Similar to MBP peptide, digestion of insulin peptide at m/z 1774Da by 
the cathepsin mixture did not destroy the peptide (Supplementary Fig. 7). The only other 
fragment detected post digestion of insulin B7–23 was a previously described epitope 
register for binding to I-Ag7. 37–39 In all, the trend seems to hold that immunodominant 
autoantigens are less susceptible to cathepsin digestion as compared to dominant epitopes 
from external pathogens (Table 1).
A destructive potential of CatD in MHC II antigen processing has been reported40. In light 
of resistance to our cathepsin mix, it was of interest to evaluate whether CatD or CatE might 
destroy the dominant epitopes from autoantigens during antigen processing and epitope 
selection. We tested this potential in a cellular IFN-γ ELISPOT assay in combination with 
pharmacological inhibitors of CatD/E, Pepstatin A and a cell penetrating variant of it, 
Pepstatin A-Penetratin (PepA-P).41 The results depicted in Supplementary Fig. 8 indicate 
that inclusion of PepA or PepA-P did not significantly reduce generation of 
immunodominant epitopes of three antigens tested; recombinant influenza HA1, influenza 
H5N1, and collagen II. This was in sharp contrast to the complete inhibition of the dominant 
epitope generation in the presence of CatB inhihitor, CA-074ME in agreement with data 
mentioned above. We conclude that CatD/E may not have a critical role in generation of 
immunodominant epitopes during MHC class II antigen processing, although further 
experiments would be necessary to exclude this possibility.
DM increases the abundance of dominant epitope
To find out how DM influences peptide selection, we compared two parallel samples 
assembled for processing of H5N1--rHA1 with or without DM. The immunodominant 
peptide at m/z 1814Da was detected in both samples and that the repertoire of eluted 
peptides remained unchanged, although, the intensity of m/z 1814Da peak was higher in the 
presence of DM (Fig. 8). To evaluate the relative quantities of the peak in two samples, we 
used Selected Reaction Monitoring (SRM). Label-free mass spectrometry methods for 
relative quantitation of MS peaks have the advantage of experimental simplicity and 
applicability. In label free quantitation, protein profiling comparisons are based on the 
relative intensities of extracted ion chromatograms. This approach therefore, does not 
require any metabolic, chemical and enzymatic labeling.42,43
Fresh samples containing equal starting materials (same amount of DR1 and rHA1 protein) 
were prepared in the presence, or absence of DM and the eluted peptides were analyzed by 
liquid chromatography tandem mass spectrometry (LC MS/MS). The m/z 1814Da peak of 
HA(259–274) was detected by MALDI first (Fig. 8). For relative quantification of this 
peptide, the samples were run on LTQ mass spectrometry and HA(259–274) was detected as 
doubly charged ions at m/z 907Da. The MS2 profile of the doubly charged ions produced 
two major daughter ions at m/z 1110 and 1181Da (Fig. 9a). The peak area values from 
extraction ion chromatograms of 1110Da or 1181Da daughter ions in samples with or 
without DM are shown in Fig. 9b and 9c and were estimated as 3356 and 3064 in the 
presence of DM, versus 626 and 597 without DM accordingly. Both daughter ions showed 
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greater area and higher intensities in the presence of DM. None of those daughter ions were 
detected in the background samples. Thus, H5N1-rHA1 derived HA(259–274) was enriched 
in the presence of DM by about five folds. These data suggests that DM influences the 
amount of epitopes captured by DR1.
Discussion
Our reductionist system for MHC class II molecules composed of only five soluble purified 
components has proved to be sufficient for antigen processing and the selection of 
immunodominant epitopes. Because of its defined nature, this system can lend itself to 
elucidating steps involved in antigen processing and deciphering molecular mechanisms 
involved in epitope selection. Here, we examined four antigens from pathogens and six 
autoantigens, known for their role in autoimmune diseases, and found clear differences in 
processing of the two types of antigens. We show that prior digestion of external proteins 
with cathepsins eliminates the capture of immunodominant epitope by HLA-DR; 
conversely, if antigen is first captured by HLA-DR in the presence of HLA-DM, dominant 
epitopes are selected successfully. A different picture emerged for examples of autoantigens. 
We learned that epitopes from autoantigens were less sensitive to destruction by the 
enzymes in the system. In fact, the core sequences of the dominant epitopes of autoantigens 
were mostly resistant to cathepsin digestion.
Two major hypotheses regarding antigen processing pathways have been put forward 
reviewed by Trombeta and Mellman.44 In one model, ‘bind first, cut/trim later’, described 
by Sercarz proposes that MHC molecules scan the length of protein antigens to find the best 
fitting epitopes.2 Based on the second model, peptides are cut first and then chosen for 
presentation to T cells. Our findings here comply with both models. With respect to the 
antigens from external sources our data fits the former model, but with respect to 
autoantigens the latter model is more suitable. A number of studies support bind first cut 
later model: a single cut by asparaginyl endopeptidase in tetanus toxoid facilitated 
presentation of the dominant epitope to specific T cells.45 Mimura et al provided evidence 
for the ‘bind first, cut/trim later’ model for a tumor antigen46, Sette et al showed denatured 
proteins binds MHCII47, Runnel et al demonstrated protein binding to MHC was enhanced 
by DM48, and Castellino et al provided evidence for binding of both I-Ak and I-Ek 
molecules to HEL.49
Consistent with ‘binding first, trimming later’ model, accessibility of dominant epitopes for 
binding to MHC II is another parameter that might contribute to preferred epitope selection 
during antigen processing.50 In our system, the HA(306–318) epitope is located at the C-
terminus of the rHA1 possibly offering an advantage for its capture by MHC II; it forms 
DM-resistant complexes with DR1. Accordingly, HA(306–318) will be protected from 
proteolysis and will be displayed at a higher abundance relative to other potential epitopes 
that are located further away from the protein termini. This might explain why many known 
immunodominant epitopes are located at the C or N-termini51–53, or on flexible strands of 
protein antigens.50 A popular model for epitope selection is the intrinsic affinity of peptide 
for MHC II7, although there are also a number of publications that report lack of correlations 
between binding affinity and immunodominance.20,54,55 It has now been documented that a 
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peptide/DR1 complex that has an empty or partially filled P1 pocket is a favorable substrate 
for interaction with DM, whereas a compact and rigid conformation with filled P1 pocket is 
an unfavorable substrate.13,56
The autoantigen-derived epitopes we tested resisted digestion by the cathepsins in the 
system. Because of reliance of autoimmune epitopes on cathepsins, it is possible to 
hypothesize that such epitopes would not be generated in the thymus and thus T cells 
reactive to them would not be deleted.37 In the periphery however, it is likely that 
autoantigens are generated in extracellular matrix where many proteases are already at work, 
and that only epitopes that survive such milieu may get a chance to be further processed and 
presented by APCs. A member of the family of matrix metalloproteinases is gelatinase B 
(MMP-9) that is known for its role in generating collagen II fragments supports this 
interpretation.57 It is fair to say that under inflammatory conditions generated by infections 
or other causes collagen fragments are generated by MMP-9 and are picked up by the APCs, 
which process and present them to the T cells. Despite being sensitive to DM-mediated 
dissociation, but because of its resistance to the cathepsins, collagen epitope can rebind to 
the MHC II and presented. Another example we tested was the thyroglobulin dominant 
epitope, which has been reported to induce thyroiditis. It is documented that this epitope is 
proteolysed in the thyroid tissue by multiple cathepsins at neutral pH and then is taken up by 
the APCs.30,58 We showed that the DR3 binding core of this epitope is resistant to further 
cleavage by the cathepsins. A third example we tested was a uveitis (EAU) inducing 
peptide, which was reduced by two residues at its C-terminus, which did not reduce its 
effectiveness in inducing EAU in DR3 transgenic mice.29 Both EAU and Thyroglobulin 
dominant epitopes were resistant to DM-mediated dissociation, suggesting that autoantigens 
may or may not be DM-sensitive. We also tested a DR2 restricted MBP(84–102) peptide 
which followed the same trend as the other autoantigens tested. Interestingly, it has been 
reported that MBP is a substrate for CatS digestion, although the major cutting sites fall 
outside the core of immunodominant epitope of MBP. It is only under extreme conditions, 
i.e., 20h incubation with CatS, the immunodominant epitope might also be cut.59 Clearly, 
there are many cathepsins in the cellular environment but not all are involved in the 
generation and selection of the dominant epitopes, and/or have redundant roles. In addition, 
activities of cathepsins are tightly regulated 5,60,61 and vary by cellular activity or 
maturation. CatD and E have been proposed to have destructive roles for myoglobin 
presentation40. We tested whether inhibition of CatD/E in cells would affect presentation of 
dominant epitopes in three of our antigens, and it appeared that the effect if any was 
incremental. While CatD/E do not appear to have a major role in dominant epitope selection 
for the antigens tested here, it is possible that they may be involved in processing of other 
antigens. Only further experiments can attest their contributions to epitope selection.
Our model was verified by testing vaccinia epitope I6L(338–352) that has previously been 
identified as an immunogenic epitope using peptide elution studies from DR1 expressing 
DC62. Exposure to our standard cathepsins destroyed this peptide leaving a cleavage 
product, SSFPVPT, which was too short to bind DR1 stably. Moreover, when examined for 
DM-mediated sensitivity, I6L(338–352)/DR1 complex was DM sensitive (Supplementary 
Fig. 9). According to our model, I6L(338–352) cannot be an immunodominant epitope as it 
is sensitive to both cathepsins and DM. Indeed, this epitope did not generate a primary 
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response in CD4 T cells from DR1+ individuals; only after a boost, T cells responded to this 
peptide moderately.62
Using our cell-free antigen processing system we have presented data to indicate there are at 
least two different paths for processing of dominant epitopes that are derived from 
autoantigens versus pathogen-derived antigens. We find that both cathepsin sensitivity and 
DM sensitivity play key roles in determination of immunodominance. Contribution of 
endosomal proteases, CatB, CatH and CatS, combined with DM effects critically influence 
the repertoire of peptides captured by DR molecules. Indeed, we have obtained evidence for 
the significance of CatB and CatS in processing of H5N1-rHA1 and collagen II proteins for 
presentation of H5N1-HA(259–274) and CII(280–294) epitopes ex vivo. Using a specific 
chemical inhibitor of CatB and CatS.19 We find that processing and presentation of 
HA(259–274) and CII(280–294) epitopes were completely inhibited cytokine production by 
specific T cells in culture.
The two paths can be described as a) immunodominant epitopes are selected by DM and 
retained by DR molecules, while epitopes that are DM-sensitive are removed and destroyed 
by the cathepsin, or b) for autoantigens tested here, cathepsin resistance is the key 
determinant while DM-sensitivity can be an added advantage, but is not an absolute 
necessity. Importantly, the nondominant epitopes are sensitive to both DM and cathepsins: 
DM dislodges those epitopes from the MHCII groove, and the cathepsins destroy them. The 
net result is that most of the MHC molecules will end up with epitopes that are bound to 
MHCII very tightly, or not so tightly, but because of resistance to digestion by the 
cathepsins they are dislodged by DM and can rebind. The important net result of all these 
events is that the immunodominant epitopes gain relative abundance, as we have shown by 
quantitative MS and as suggested for cellular processing.54
Methods
Production of Recombinant Proteins
Soluble DR1*01:01 was produced as described.12 In brief, bacculovirus DNA (BaculoGold; 
PharMingen) and transfer vectors carrying DR α and β chain genes were transfected together 
into Sf9 insect cells to produce recombinant viruses. Hy5 cells were infected with the 
recombinant viruses and DR1 proteins were purified from culture supernatants with 
immunoaffinity chromatography columns with monoclonal antibody L243 to DR1 (purified 
from HB-55 hybridoma; American Type Culture Collection). Soluble HLA-DM was 
expressed by Hy5 cells transduced with recombinant bacculovirus containing extracellular 
domains of the genes encoding the α- and β-chains of human HLA-DM. The truncated DM 
α- and β-chains were genetically modified to contain the Flag epitope (DYKDDDDK) and 
the c-Myc epitope (EQKLISEEDL) respectively, at their C termini. Protein was purified 
from culture supernatants with monoclonal antibody to M2 (anti-Flag) sepharose resin 
(Sigma), was eluted with 0.1 mg/ml of Flag peptide in 0.05% (weight/volume) sodium azide 
in PBS, was further purified by gel-filtration chromatography (Superdex 200 HR 10/30 
column; Amersham Pharmacia) and was stored at −80°C at a concentration of about 1 
mg/ml in 0.05% (weight/volume) sodium azide in PBS. Recombinant influenza 
hemagglutinin (rHA1) was produced as described previously in E. coli18. H5N1-rHA1 from 
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strain A/Vietnam/1203/2005, purified from 293 cells, was purchased from commercial 
sources (eEnzyme, Gaithersburg, MD, USA). H5N1-HA protein was obtained from BEI 
Resources. Biotinylated HLA-DR4 (DR4)/CLIP and HLA-DR3 (DR3)/CLIP were obtained 
from NIH Tetramer Core Facility (Atlanta, GA). Bovine type II collagen (bCII) was 
purchased from Chondrex (Chondrex, Redmond, WA, USA).
Peptides synthesis and peptide labeling
Peptides human CLIP, hCLIP(89–105), KMRMATPLLMQALPM, HA(Y308A), 
PKAVKQNTLKLAT, CII(280–294), CAGFKGEQGPKGEPGPOH, and CII(954–968)2OH, 
FTGLQGLPOHGPPOHGPSGC were synthesized by Global Peptide (currently Pi 
Proteomics, Huntsville, AL, USA). HA(306–318) peptide, PKYVKQNTLKLAT, H5N1-
HA(259–274), SNGNFIAPEYAYKIVK, MBP(89–101), CVHFFKNIVTPRTP, and 
hSA(291–306), NRERRGIALDGKIKHE, were synthesized by Elim 
Biopharmaceuticals.Inc. Thyroglobulin peptide Tg(2098–2112), LSSVVVDPSIRHFDV 
was synthesized by GenScript.Inc. All peptides were at 90–95% purity as analyzed by 
reverse-phase HPLC, and their identities were confirmed by mass spectrometry. Tg(2098–
2112) and hSA(291–306) were fluorescently labeled at N-termini27. Fluorescent labeling of 
CII peptides was through an added N-terminal cysteine as described previously12.
Peptide binding and dissociating assays
Prior to setting up the peptide binding assays62, DR3/CLIP complexes were thrombin 
cleaved for 1h at room temperature (Thrombin was purchased from Novagen, EMD 
Millipore chemicals, Billerica, MA, USA). After the thrombin cleavage, 500μM 
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA) was added to 
inactivate the enzyme. For binding assays, DR3 (1μM) was incubated for various times in 
the presence or absence of 1μM DM together with 50μM fluorescence-labeled peptides in 
citrate phosphate buffer (pH 5.0) at 37°C. Unbound peptide was removed by spin columns 
(Sephadex G-50 equilibrated with PBS/0.1% filtered non-fat milk) at pH 7.4. Fuorescence 
emission of the FITC–peptide–DR complexes was measured at 25°C and 514–516 nm with 
excitation at 492 nm on a Fluoromax3 spectrofluorometer (Horiba Jobin-Yvon, Kyoto, 
Japan) with a slit width of 2nm. For dissociation assays, a stock solution of DR1 or DR3 
(10μM) was incubated with fluorescence-labeled peptide (150μM) in PBS/NaN3 for 3 days 
at 37°C to yield maximal loading. Unbound fluorescent peptide was removed by spin 
columns. Dissociation of fluorescent peptide/DR complexes (1μM) was monitored in 
samples incubated for different length of times in the presence of excess unlabeled 
competitor peptide (100μM) with or without DM. Fluorescence signal was measured after 
one more spin column separation as described above.
Proliferation and cytokine assays
HLA-DR1 (DRB1*0101) transgenic mice (originally obtained from Dr. Denis Zaller, 
Merck) expressing a fusion product of the DR1 binding groove and the membrane proximal 
domain of I-E molecules21 were backcrossed to MHC class II KO mice for 12–16 
generations to eliminate endogenous class II proteins (I-Af) and then were inbred to 
homozygocity. DR1 transgenic mice were immunized with 100 μg type II collage proteins 
or peptides in complete Freund’s adjuvant (CFA) at the base of tail. After 8–10 days, cells 
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were harvested from the draining lymph nodes and incubated with a range of peptide and 
protein concentrations for 3 days in culture before adding [3H] thymidine (Amersham). Cells 
were then harvested and counted after a further 18–20h culture. For cytokine assays, the 
draining lymph nodes of the immunized mice were collected after 10 days and cells (5×105) 
were incubated with a range of peptide and protein concentrations. Culture supernatants 
were collected 48h later and IL-2 concentrations were measured by enzyme-linked 
immunosorbent assay (ELISA) (R&D System). The optical density was measured in an 
ELISA reader (Dynex Technologies) at 450 nm and a reference wavelength of 570 nm. For 
IFN-γ ELISPOT assay (BD Biosciences), cells (8 ×105) from the draining lymph node were 
incubated with peptides (5μM), or proteins (0.25μM) for 24h or 48h in the presence or 
absence of cathepsin inhibitor, CA-074ME (Calbiochem), (5–10μM), Pepstatin A (Sigma) 
(100–200μM), or Pepstatin A-Penetratin (Calbiochem), (10–20μM),. After the incubation, 
ELISPOT plate was analyzed with the CTL Immunospot Analyzer plate reader and software 
(Cellular Technology Limited).
Detection of SDS-stable HLA-DR1-antigen complexes by SDS-PAGE
Samples were prepared by incubating DR1 (1μM) with various combinations of the 
following: rHA1 (2.7μM), HA(306–318) (300μM), and DM (1μM) in citrate phosphate 
buffer pH 5.0/0.05% NaN3 for 3h in 37°C waterbath. Following incubation, pH was 
adjusted to 7.4 with either 0.2M sodium phosphate dibasic or 1M Tris-HCl pH 8.0 and the 
samples were mixed with a modified Laemmli buffer with 0.1% SDS final concentration 
and no reducing agents. The samples were resolved without boiling on 12% polyacrylamide 
gels and were silver stained63. For Western Blot experiments, various combinations of 
DR1(1μM), DM (0.5μM), rHA1 (2μM), or HA(306–318) (300μM) were incubated in citrate-
phosphate buffer pH 5.0 overnight at 37°C. The pH was readjusted to 7.4 and the samples 
were mixed with Laemmli buffer containing 0.1% SDS and 2.5% 2ME. They were either 
not boiled (room temperature), or boiled prior to loading on 10% SDS-PAGE. Samples on 
gel were transferred to PVDF membranes; DR1/Protein complexes were detected by anti-
His mAb (1:10,000) (Invitrogen) or CHAMP2 (1:4,000) (Rabbit polyclonal anti DR1 serum 
(Gift from Dr. Larry Stern), followed by staining with anti-mouse HRP (1:5,000) or anti-
Rabbit HRP Ab (1:5,000) respectively.
Surface Plasmon Resonance Experiments
Biotinylated DR4/CLIP was thrombin cleaved for 1h at room temperature and incubated 
with 100 folds molar excess of HA(Y308A) for 3 days at 30°C to generate peptide receptive 
DR4. After removing unbound HA(Y308A) by spin column filtration equilibrated in PBS/
0.05% NaN3, DR4-HA(Y308A) (5μM) complexes were incubated with denatured H5N1-
rHA1 protein (eEnzyme) (2μM) and DM (1μM) for 20 min at 37°C. Immediately after, 
DR4-H5N1-rHA1 protein complexes were injected over Sensor chip SA (streptavidin) (GE 
Healthcare Biosciences, Waukesha, WI, USA). Receptive DR1 (incubated with excess 
HA(Y308A) for 3 days at 37°C) or HA(306–318) bound DR1 (2μM) (closed DR1) were 
injected over H5N1-rHA1 bound DR4 immobilized surface in the presence of DM (1μM). 
All protein solutions were diluted in the running buffer composed of citrate-phosphate pH 
5.5 with 150 mM NaCl, 0.005% Tween-20 and 0.05% NaN3. Measurements were done at 
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37°C with flow rates ranging between 1–3μL/min. Binding sensograms were collected on a 
BIAcore 1000 instrument (GE Healthcare Biosciences, Waukesha, WI, USA).
Mass Spectrometry
Sample preparations for MS analyses—HLA-DR1, protein antigen and HLA-DM 
were incubated in citrate phosphate buffer (pH 5.0–5.2) at 37°C for 3h before adding 
cathepsin B (bovine spleen, Sigma), cathepsin H (human liver, Calbiochem), and cathepsin 
S (human recombinant produced in E.coli, Calbiochem) in 6 mM L-Cysteine and 4 mM 
EDTA for an additional 2–3h. For synthetic peptide digestion samples, peptides were 
incubated in citrate phosphate buffer (pH 5.0) at 37°C for 1h with cathepsins B, H, and S 
and 6mM L-cysteine and 4mM EDTA. For some experiments with type II collagen and 
rHA1 proteins, only cathpesin B and H were added while most experiments were done with 
all three cathepsins, B, H and S. After digestion, the pH was adjusted to 7.4, 10μM 
iodoacetamide was added, and DR1 was immunoprecipitated with HLA-DR specific mAb 
(L243) conjugated Sepharose beads. Bound peptide was eluted with TFA (1%) and filtered 
through a 10 kDa MWCO Microcon (Millipore) and lyophilized. Samples from synthetic 
peptide digestions were filtered through a 10kDa MWCO Microcon, washed with 10% 
MeOH/0.1% TFA, and lyophilized. Lyophilized filtrates were resuspended in 10μl 0.1% 
TFA and zip tipped (Millipore) for analysis by mass spec.
vMALDI-LTQ XL analysis—Lyophilized samples were re-suspended in 5–10μl 50% 
ethanol/50% water/0.2%TFA. 0.5μl of re-suspended sample was spotted, dried, and covered 
with 0.5μl matrix (either 2,5-Dihydroxybenzoic acid, 40–50mg/ml in 50% ethanol/
50%water/0.15%TFA or α-Cyano-4-hydroxycinnamic acid, 2.5mg/ml in 50%ethanol/50% 
water/0.15%TFA). First Full MS (1100–4000Da mass range) was acquired on a vMALDI-
LTQ XL (Thermo Fisher Scientific) and then MS2 and MS3 CID (collision induced 
dissociation) spectra were acquired on peptides of interest. Spectra were manually acquired 
using CPS plate motion, 2 microscans, 0 sweep scans, automatic gain control (AGC) feature 
“on”, automatic scan filtering (ASF) “on” and set on 3000 for Full MS and 200 for MSn, 
and accumulating 10–15 scans for Full MS and 15–25 scans for MSn.
Data analysis—Full MS spectra were first visually scanned to find peptides of interest. 
MSn data collected for the peptides of interest were searched with Bioworks 3.3.1 SP1 
(Thermo Fisher) against a custom-built database. The custom database contained protein 
sequences of all components presented in the sample reactions. MSn data was searched with 
the following parameters; no enzymes, monoisotopic precursor and fragment ions, 2 missed 
cleavage sites, peptide tolerance of 1–2Da, fragment ion tolerance of 1Da, and variable 
modifications including carboamidomethylated cysteine, oxidized methionine, and 
methionine with 48Da loss for MS3.
LTQ analysis for relative quantification of H5N1-rHA1 immunodominant 
epitope—Lyophilized samples of H5N1-rHA1 were resuspended in water-1%TFA/0.2% 
acetonitrile. 5μl was loaded on nano-LC-ESI/MS/MS platform connected to LTQ XL 
(ThermoFisher) interfaced with a 2D nanoLC system (Eksigent, www.eksigent.com). 
Peptides were fractionated by reverse-phase HPLC on a 75μm × 100mm C18 column (YMC 
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ODS-AQ 5um particle size, 120A pore size) with a 10μm emitter (New Objective) using 10–
40% acetonitrile/0.1% formic acid gradient at 300nl/min over 15min time. Using selected 
reaction monitoring (SRM) two transitions, 907.6Da to 1110.5 (+/−1.0Da) and 907.6 to 
1181.5 (+/−1.0Da) were monitored using 2.2kV source voltage, collision energy of 35V, Q 
= 0.250; activation time=30.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cathepsin B is a critical endosomal protease for generation of CII(280–294) and H5N1-
HA(259–274) immunodominant epitope
ELISPOT assay measuring IFN-γ production of T cells isolated from DR1-transgenic mice 
immunized with CII(280–294) (a), or H5N1-HA(259–274) (b) in CFA. Cells were 
stimulated with peptides or proteins in vitro for 24h (a) or 48h (b) in the presence or absence 
of cell-permeable cathepsin B inhibitor, CA-074ME. Data shown here are representative of 
three independent experiments. Error bars are defined as SD.
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Figure 2. Cathepsins and HLA-DM are necessary for the selection of the immunodominant 
epitope of type II collagen
(a–d) Mass spectra of peptides eluted from DR1 containing MMP9-fragmented bCII. e 
shows the negative control reactions that do not contain the antigen. DR1 used in all 
experiments shown here (except for in sample d) was pre-incubated with HA(Y308A) to 
forms short-lived complexes with DR1(DR1/HA(Y308A) complex (T1/2 ~34 min) to induce 
a peptide-receptive conformation23. The m/z 1258Da peak seen in e is background peptide 
peak an insect-derived protein that binds to a portion of purified DR1 and is present in most 
DR1 preparations. The peaks in the shaded area represent post-translationally modified 
variants of a dominant peptide composed of residues 273–305 of bCII 
(QTGEPGIAGFKGEQGPKGEPGPAGVQGAPGPAG). Mass species in red represent CII-
derived peptides containing the immunodominant core CII(282–289). Non-dominant 
peptides are shown in blue. Background peptide species are labeled in black. These 
experiments were repeated more than three times and two cases all three cathepsins were 
included with similar results. (f) Proliferation of T cells isolated from DR1-transgenic mice 
immunized with bCII protein in CFA in response to stimulation with, CII(280–294), 
CII(954–968), or CLIP(89–105) in vitro. Cellular proliferation was measured by [3H] 
thymidine incorporation (Left panel). The data shown here is a representative result of one 
mouse out of four individual mice tested. Error bars are defined as SD.
IL-2 ELISA was performed from supernatant collected from in vitro culture of another three 
individual mice immunized with CII protein/CFA. Cell culture supernatants were removed 
after 48h culture (Right panel). (g–h) Dissociation assay of fluorescently labeled non-
dominant epitope, CII(954–968) and immunodominant epitope CII(280–294) from DR1. 
Fluorescently labeled CII(954–968)/DR1 complexes (g), or fluorescently labeled CII(280–
294)/DR1 complexes (h) were dissociated in the presence of 100μM of unlabeled HA(306–
318) at 37°C for the indicated times in the absence (square), or presence of DM (circle). The 
fluorescence of the labeled complex before dissociation is arbitrarily assigned a value of 
100, and fluorescence after dissociation is expressed as a fraction of fluorescence before 
dissociation. Representative of three dissociation experiments.
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Figure 3. Type II collagen-derived immunodominant peptides are resistant to cathepsin 
digestion
(a–e) Mass spectra of peptides eluted from DR1 are shown for m/z range of 1400–3600Da. 
(a) MMP9-bCII was incubated with DR1 and DM for 3h. (b) MMP9-bCII was first exposed 
to cathepsins B and H for 3h, (c) for 1h or (d) for 15min, and then incubated with DR1 and 
DM for additional 3h. (e) Mass spectrum of peptides eluted from DR1 when all components 
of the cell-free assay were mixed simultaneously and incubated together for 3h. As in Fig 1, 
the peaks in the shaded area between 3000–3550Da represent PTM variants of the dominant 
peptide bCII(273–305). Immunodominant peptides are labeled in red and non-dominant CII 
peptides are shown in blue. CII protein pre-digestion assays were repeated three times. (f) 
Mass spectra of synthetic CII(280–294) immunodominant peptide, and (g) Mass spectra of 
synthetic non-dominant CII(954–968) that were directly exposed to the cathepsins, B, H, 
and S for 1h at 37°C. Top spectra in both f and g show synthetic peptides without treatment. 
Middle spectra show samples incubated with the cathepsins. Bottom spectra correspond to 
the background samples containing only cathepsins. The peak at m/z 1338Da of the middle 
spectrum in (g) is not derived from the collagen CII(954–968) there is a background peptide 
from cathepsins. These experiments were repeated three times.
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Figure 4. Degradation of HA(306–318) by the cathepsins outcompetes its capture by HLA-DR1
(a–e) The mass spectra of peptides eluted from DR1. Mass species in red represent rHA1 
fragments containing the DR1 restricted immunodominant HA(306–318) epitope. Peptides 
highlighted in blue represent other rHA1-derived peptides eluted from DR1. Recombinant 
HA1 was first exposed to cathepsins B and H for (a) 3h, (b) 1h, or (c) 15 minutes, followed 
by incubation with DR1 and DM for 2 h at 37°C. (d) Mass spectrum of peptides eluted from 
DR1 when all components were mixed simultaneously and incubated together for 3h. (e) 
Mass spectra of peptides eluted from DR1 when rHA1 was incubated with DR1 and DM for 
3h first, and then incubated with the cathepsins for additional 2h. (f) Sensitivity of synthetic 
HA(306–318) to the cathepsins tested by direct exposure to cathepsins B, H, and S. Top 
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spectrum shows HA(306–318) peptide alone. Middle spectrum is the sample reaction 
containing HA(306–318) incubated with the cathepsins for 1h at 37°C, and the bottom 
spectrum shows the background sample containing the cathepsin mix without the synthetic 
peptide. Experiments were repeated three times.
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Figure 5. Immunodominant epitope of H5N1-rHA1 is sensitive to the cathepsins
(a–c) The mass spectra of peptides eluted from DR1 when (a) denatured H5N1-rHA1 (A/
Vietnam/1203/2004) was first incubated with DR1 and DM, and then exposed to cathepsins 
B, H, and S, or (b) when denatured H5N1-rHA1 was first exposed to the cathepsins for 3h 
and then incubated with DR1 and DM. (c) is the background spectrum. Boxed mass species 
represent H5N1-rHA1 fragments containing the DR1 restricted immunodominant HA(259–
274) epitope. (d–e) mass spectra of the synthetic HA(259–274). (d) Similar to the procedure 
in Figure 3f, the top panel shows undigested HA(259–274) peptide. Digested peptide with 
the cathepsins is shown in the middle panel, and the bottom panel shows cathepsins alone as 
a background control. (e) Mass spectra of peptides eluted from DR1, after 3h incubation of 
DR1 with HA(259–274) peptide alone (top), HA(259–274) digested with the cathepsins 
(middle), or the cathepsins alone (bottom). Baculovirus-derived peptide CL(13–23) was 
detected in every spectra from samples containing DR1. Experiments were repeated three 
times.
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Figure 6. Intact protein antigens form complexes with HLA-DR
(a–b) SDS-stable complex formation with intact proteins and DR1. Various combinations of 
DR1, DM, rHA1, and synthetic HA(306–318) peptide were incubated in citrate-phosphate 
buffer pH 5.0 for 2h at 37°C. Different combinations of proteins and peptides (shown in 
different lanes) were analyzed by “gentle” SDS-PAGE in which samples are not boiled prior 
to loading and (a) silver-stained, or (b) western blotted. Polyclonal anti-DR1 serum 
(CHAMP2) or anti-His antibody was used for detecting protein/DR complexes in (b). 
Recombinant HA1 protein/DR1 complexes (marked by *) migrated at approximately 96 kD 
molecular mass. Unbound rHA1 protein migrated at ~45kD (marked by 〉), HA(306–
318)/DR1 migrated at around 60kD (marked by ➢), and DR1 is shown at about 50kD. B, 
boiled, NB, non-boiled.rHA1/DR1 complexes were estimated to migrate at 96 kD molecular 
mass in both a and b.
(c) Simultaneous binding of two DR alleles to H5N1-rHA1 protein as detected by BIAcore. 
Biotinylated DR4/HA(Y308A) complex was incubated with denatured H5N1-rHA1 protein 
for 20min at 37°C in the presence of DM, during which HA(Y308A) would dissociate and 
be replaced by H5N1-HA1 protein. At the end of the incubation, DR4/H5N1-rHA1 protein 
complex was injected over the streptavidin coated sensor chip (SA) for 600 seconds and 
produced 3500 RU, shown as time zero. Then, receptive DR1 (pre-incubated with 
HA(Y308A) (red), or closed HA(306–318) complex (as control) (blue) were injected over 
H5N1-rHA1 bound DR4 immobilized surface in the presence of DM for 3000 seconds after 
which running buffer was injected over the chip to monitor the binding of proteins. 
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Sensograms from both injections are superimposed in the figure for comparison. Negative 
sensograms observed during the injection are due to changes in buffer conditions between 
the running buffer and the sample buffer. Binding of the protein of interest to the 
immobilized protein are shown in the Response Unit (RU) indicating the RU difference 
between the injection start time versus injection end time.
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Figure 7. HLA-DR3 binding core region of autoantigen derived immunodominant epitopes show 
resistance to the cathepsins and HLA-DM
(a–b) Mass spectra of retinal arrestin derived dominant epitope, hSA(291–306), and 
thyroglobulin-derived dominant epitope, Tg(2098–2112), after digestion with the cathepsins. 
Untreated synthetic peptides (a) hSA(291–306) or (b) Tg(2098–2112) are shown on the top 
spectra in a and b. Peptides were incubated with cathepsin B, H, and S for 1h at 37°C 
(shown in the middle spectra). Background controls that included cathepsins alone are 
shown in the bottom spectra. The experiments were repeated twice.
(c–d) Dissociation kinetics of fluorescently labeled hSA(291–306) or Tg(2098–2112) from 
DR3. (c) FL-hSA(291–306)/DR3 or (d) FL-Tg(2098–2112)/DR3 complexes were formed 
over a three day incubation with peptides in 37°C and the unbound peptides were removed 
by spin column separation. Dissociation experiments were in the presence of 100μM 
unlabeled hSA(291–306) or 100μM unlabeled Tg(2098–2112) peptides at 37°C for the 
indicated time in the presence (circle) or absence (square) of DM. The fluorescence of the 
labeled complex before dissociation was arbitrarily assigned a value of 100.0, and 
fluorescence after dissociation is expressed as a fraction of fluorescence before dissociation. 
Dissociation experiments were repeated twice.
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Figure 8. Repertoire of H5N1-rHA1 derived peptides appears the same with or without DM
Samples containing equal starting materials (same amount of DR1 and rHA1 protein) were 
prepared in the presence, or absence of DM and the eluted peptides were analyzed by 
MALDI. (a–d) Native form of H5N1-rHA1 protein, DR1, and the cathepsins B, and H, and 
S were incubated in the (a) presence or (b) absence of DM. (c) and (d) are background 
spectra for samples a and b, respectively, from reactions not containing H5N1-rHA1. 
Immunodominant epitopes, HA(259–274) (SNGNFIAPEYAYKIVK), and HA(259–278) 
(SNGNFIAPEYAYKIVKKGDS), are shown at m/z 1814.7Da and 2200.8Da. The 
experiments were repeated three times.
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Figure 9. DM increases the abundance of dominant epitope
Quantitation ofHA(259–274) epitopes obtained in samples with or without DM by liquid 
chromatography (LC) combined with Linear Ion Trap Quadrouple tandem mass 
spectrometry (LC-LTQ MS/MS). Samples containing equal starting materials (same amount 
of DR1 and rHA1 protein) were prepared in the presence, or absence of DM and the eluted 
peptides were analyzed. For relative quantification of this peptide, the samples were rerun 
on LTQ mass spectrometry and HA(259–274) was detected as doubly charged ions at m/z 
907 Da. (a) The MS/MS profile of the doubly charged ions produced two major daughter 
ions at m/z 1110 and 1181Da. (b) The base peak area values from extraction ion 
chromatograms of 1110 Da or (c) 1181 Da daughter ions in samples with or without DM are 
shown and were estimatedas 3356 and 3064 in the presence of DM, versus 626 and 597 
without DM accordingly. Neither of those daughter ions were detected in the background 
samples. (BP -base peak; AA – automated area calculated using Genesis peak detection 
algorithm). The experiments were repeated twice and each experiment was quantified two 
times.
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Table 1
Summary of cathepsin and HLA-DM sensitivity for epitopes tested in this study.
Epitopes tested for cathepsin 
sensitivity
MHC II restriction Peptides detected on MALDI after 
digesting synthetic epitope with 
cathepsins
HLA-DM susceptibility
HLA-DR1 (DRB1*0101) PKYVKQNTLK (m/z 1218 Da) resistant
HLA-DR1 (DRB1*0101) SNGNFIAPEYAYKIVK (m/z 1814 Da)
SNGNFIAPEY (m/z 1111 Da)
resistant
HLA-DR1 (DRB1*0101) None-detected resistant
HLA-DR1 (DRB1*0101) SSFPVPT (m/z 734 Da)
GIYTYRIIK (m/z 1126Da)
sensitive
HLA-DR1 (DRB1*0101) AGFKGEQGPKGEPGPOH (m/z 1471 Da) sensitive
HLA-DR1 (DRB1*0101) None-detected sensitive
HLA-DR3 (DRB1*0301) NRERRGIALDGKIKHE (m/z 1892 Da)
NRERRGIALDGKIK (m/z 1627 Da)
resistant
HLA-DR3 (DRB1*0301) LSSVVVPSIRHFDV (m/z 1669 Da)
SVVVDPSIRHFDV (m/z 1469 Da)
LSSVVVDPSIRHF (m/z 1456 Da)
SVVVDPSIRHF (m/z 1255 Da)
LSSVVVDPSIR [m/z 1171 Da)
resistant
HLA-DR2a (DRB5*0101)
HLA-DR2b (DRB1*1501)
VHFFKNIVTPR (m/z 1357 Da)
HFFKNIVTPR (m/z1258 Da)
FFKNIVTPR (m/z 1121 Da)
sensitive
HLA-DQ8 (DQA1 *0301/
DQB1 *0302)
I-Ag7
n.d.
I-AK DSAFDVLSFTAEEKAGVYK (m/z 2078 
Da)
FTAEEKAGVYK (m/z 1242 Da)
DSAFDVLS (m/z 853 Da)
AEEKAGVYK (m/z 994 Da)
n.d.
n.d. (not determined)
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